Arvinas Doses First Patient in Phase 1/2 Trial of First-in-Class HPK1 Degrader
ARVN is trading near its 52-week low of $6.97 (9.0% above the low).
Summary
Arvinas has dosed the first patient in its Phase 1/2 trial of ARV-6723, an oral PROTAC targeting HPK1 for advanced solid tumors. This is the company's first immuno-oncology candidate and the first HPK1 degrader to enter the clinic in the US. Preclinical data showed single-agent activity in anti-PD-1 resistant models, supporting both monotherapy and combination arms. The trial will assess safety, PK/PD, and preliminary antitumor activity. This milestone expands Arvinas' pipeline beyond its existing oncology and neurology programs, and follows strong Q2 2026 results driven by the VEPPANU deal.
At the time of this announcement, ARVN was trading at $7.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $496.3M. The 52-week trading range was $6.97 to $14.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.